Homeopathy and the COVID-19 Pandemic

Homeopathy and the COVID-19 Pandemic

During the COVID-19 pandemic (2020–2023), several studies explored the role of homeopathy as

either adjunctive or primary care. Observational cohorts, randomized trials, and case series have

shown promising results, particularly for individualized treatment in mild to moderate cases and

Long COVID recovery.

Documented Study Highlights

- India (hospital, moderate-severe cases): Adjunctive individualized homeopathy reduced mortality

from ~32.3% to ~15.3%.

- India (community clinics): A cohort of 211 analyzable patients showed symptomatic improvement

using Arsenicum, Bryonia, Gelsemium, Pulsatilla.

- Brazil (outpatient RCT): In mild to moderate home-treated cases, medical discharge time halved

(74.5 h vs 137.4 h).

- Austria (Long COVID): 14 of 15 patients recovered fully under individualized treatment within 37

days on average.

- Brazil (Camphora 1M prophylaxis): Ecological study showed no statistical benefit on mortality or

hospitalization.

Why Homeopathy May Have Helped

- Remedies were individualized based on symptoms, not pathology alone.

- Early treatment in mild to moderate stages prevented complications.

- Holistic care supported immune regulation without immunosuppression.

- No harmful drug interactions; treatment was safe alongside conventional therapy.

Common Remedies Used

- Arsenicum album: restlessness, exhaustion, respiratory distress

- Bryonia alba: dry cough, pain with motion, thirst

- Gelsemium sempervirens: weakness, chills, drowsiness

- Pulsatilla nigricans: congestive symptoms, emotional lability

- Phosphorus, Antimonium tart, and others were also used based on case

Summary of Research Findings

| Study / Setting | Design | Patients | Outcome Summary |

|-----------------------------------------|----------------------------------|----------------|-------------------------------------

-------------------|

| India – Hospital (ICU/moderate) | Randomized, single-blind | ~120 | Mortality halved; oxygen time

reduced |

| India – Community clinics | Observational cohort | 211 analyzed | Symptom improvement in >75%

|

| Brazil – Mild/moderate home cases | Double-blind RCT | 82 | Faster recovery (75h vs 137h) |

| Austria – Long COVID recovery | Case series | 15 | 14 fully recovered in median 37 days |

| Brazil – Camphora prophylaxis | Ecological population study | Municipalities | No benefit on

mortality/hospitalization |Further Reading and Sources

- Lidsen Journal: https://www.lidsen.com/journals/icm/icm-09-03-045

- IJRH Study: https://www.ijrh.org/article.asp?issn=0974-7168;year=2022;volume=16;issue=1;spag

e=26;epage=36;aulast=Varghese

- PLOS One Trial: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292783

- Thieme Study Brazil:

https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0044-1786511

- ResearchGate Summary: https://www.researchgate.net/publication/355991808_Homeopathy_in_

Epidemics_From_Cholera_to_1918_Spanish_Flu_Part_2